[
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Chip Stocks Surge as Holiday Trading Week Begins",
    "summary": "The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.",
    "url": "https://finnhub.io/api/news?id=71c65c1a05ee9e6dc73719d40886e93eed5aa770944d1784e184a3ec2e3e21ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734990166,
      "headline": "S&P 500 Gains and Losses Today: Chip Stocks Surge as Holiday Trading Week Begins",
      "id": 132124021,
      "image": "https://www.investopedia.com/thmb/6zY9Nw1Vxkrtr0LZqTOlpxEtPy4=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2189656773-518305a72e6c40d18af8a92063a5319b.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.",
      "url": "https://finnhub.io/api/news?id=71c65c1a05ee9e6dc73719d40886e93eed5aa770944d1784e184a3ec2e3e21ad"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Honda, Qualcomm, Broadcom, Lilly, ResMed, Tesla, Walmart, Rumble, and More",
    "summary": "Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s Zepbound for some sleep-apnea patients.",
    "url": "https://finnhub.io/api/news?id=4bde6d51360ea0b8fad5b2503ab6192fee0b2bff87740fe971915bbce331a738",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734989280,
      "headline": "These Stocks Moved the Most Today: Honda, Qualcomm, Broadcom, Lilly, ResMed, Tesla, Walmart, Rumble, and More",
      "id": 132125510,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s Zepbound for some sleep-apnea patients.",
      "url": "https://finnhub.io/api/news?id=4bde6d51360ea0b8fad5b2503ab6192fee0b2bff87740fe971915bbce331a738"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark.",
    "summary": "Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.",
    "url": "https://finnhub.io/api/news?id=fcfc54c767adccf418b6dea989587cecea41ee9e59551cb4d9968d239e2e8dce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734958500,
      "headline": "Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark.",
      "id": 132119050,
      "image": "",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one.",
      "url": "https://finnhub.io/api/news?id=fcfc54c767adccf418b6dea989587cecea41ee9e59551cb4d9968d239e2e8dce"
    }
  },
  {
    "ts": null,
    "headline": "Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound",
    "summary": "Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.",
    "url": "https://finnhub.io/api/news?id=f0f4e700791f08794dc8a84ae3835100769702ccaf743dfe32c970d4051fe499",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734981907,
      "headline": "Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound",
      "id": 132124053,
      "image": "https://www.investopedia.com/thmb/1Al6yUm6eeULcNDtRYzddJjl5cg=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2126120481-f80ae43f31204df79378fee13e344f48.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat moderate-to-severe obstructive sleep apnea in adults with obesity.",
      "url": "https://finnhub.io/api/news?id=f0f4e700791f08794dc8a84ae3835100769702ccaf743dfe32c970d4051fe499"
    }
  },
  {
    "ts": null,
    "headline": "Top Stock Movers Now: Broadcom, AMD, ResMed, and More",
    "summary": "Major U.S. indexes were mixed at midday Monday to start the holiday-shortened trading week.",
    "url": "https://finnhub.io/api/news?id=e2b6c68f054ba526d0316d2186af0324519d95ec65b5474d2c997b755a300aaa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734978838,
      "headline": "Top Stock Movers Now: Broadcom, AMD, ResMed, and More",
      "id": 132124027,
      "image": "https://www.investopedia.com/thmb/_e91aHwdjnw9qHn2JtwOeAfFwPE=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-19806700676-4876f91af7c24127be77dcdb15c28120.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Major U.S. indexes were mixed at midday Monday to start the holiday-shortened trading week.",
      "url": "https://finnhub.io/api/news?id=e2b6c68f054ba526d0316d2186af0324519d95ec65b5474d2c997b755a300aaa"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Qualcomm, Rumble: Market Minute",
    "summary": "Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute. Pharmaceutical giant Eli Lilly's (LLY) GLP-1 weight-loss drug Zepbound received approval by the US Food and Drug Administration (FDA) to treat sleep apnea. Qualcomm (QCOM) was found not to be in violation of an Arm (ARM) licensing agreement after the former's acquisition of Nuvia in 2021. Rumble (RUM) shares skyrocket by over 80% Monday morning following a $775 million investment from crypto firm Tether (USDT-USD). To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=a0f760cdacfc6456cc638add4bc84f345b1ac5196f30b4b3a70d675b567b9fac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734973829,
      "headline": "Eli Lilly, Qualcomm, Rumble: Market Minute",
      "id": 132121476,
      "image": "https://s.yimg.com/ny/api/res/1.2/NwMq9JcWw1689i8_2TSS_w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzY-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/c3987df0-c150-11ef-a3ff-d7a4d24c3b86",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Akiko Fujita highlights three of the top trending stocks and stories as part of today's Market Minute. Pharmaceutical giant Eli Lilly's (LLY) GLP-1 weight-loss drug Zepbound received approval by the US Food and Drug Administration (FDA) to treat sleep apnea. Qualcomm (QCOM) was found not to be in violation of an Arm (ARM) licensing agreement after the former's acquisition of Nuvia in 2021. Rumble (RUM) shares skyrocket by over 80% Monday morning following a $775 million investment from crypto firm Tether (USDT-USD). To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=a0f760cdacfc6456cc638add4bc84f345b1ac5196f30b4b3a70d675b567b9fac"
    }
  },
  {
    "ts": null,
    "headline": "AbCellera Biologics: Still A Concept Stock",
    "summary": "AbCellera Biologics Inc. shifts focus to developing wholly owned candidates and trades near net cash on its balance sheet. Find out why ABCL stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=40cd9556d3f136dddb37a6b86e56f88af6b2c693e32e0bd937892d824f10bbab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734971977,
      "headline": "AbCellera Biologics: Still A Concept Stock",
      "id": 132123438,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AbCellera Biologics Inc. shifts focus to developing wholly owned candidates and trades near net cash on its balance sheet. Find out why ABCL stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=40cd9556d3f136dddb37a6b86e56f88af6b2c693e32e0bd937892d824f10bbab"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea",
    "summary": "Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.",
    "url": "https://finnhub.io/api/news?id=a59f3ab0721a8504f6549a5d8692981345fe0876293c981b065feb8180c4d99f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734971804,
      "headline": "Lilly Rises on FDA Approval of Weight-Loss Drug Zepbound for Sleep Apnea",
      "id": 132128412,
      "image": "https://www.investopedia.com/thmb/D5_DX5KkvXqjZBWkyLCzX8XMhDk=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-2126120280-94c8334d07474c6883f6bb568b95693f.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.",
      "url": "https://finnhub.io/api/news?id=a59f3ab0721a8504f6549a5d8692981345fe0876293c981b065feb8180c4d99f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
    "summary": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
    "url": "https://finnhub.io/api/news?id=43d97b071a263f9bb49a3c83572213b633af95cb84fdba908a8325f163d7f5d4",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734968760,
      "headline": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
      "id": 132145561,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.",
      "url": "https://finnhub.io/api/news?id=43d97b071a263f9bb49a3c83572213b633af95cb84fdba908a8325f163d7f5d4"
    }
  },
  {
    "ts": null,
    "headline": "NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III",
    "summary": "Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.",
    "url": "https://finnhub.io/api/news?id=598033ee3fe9257406686180ff5bc20d6fb26e5cf6d8a8128f0368dbca607dbb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734966000,
      "headline": "NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III",
      "id": 132121200,
      "image": "https://media.zenfs.com/en/zacks.com/723b414aa10600faf58f7a232ec73364",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.",
      "url": "https://finnhub.io/api/news?id=598033ee3fe9257406686180ff5bc20d6fb26e5cf6d8a8128f0368dbca607dbb"
    }
  },
  {
    "ts": null,
    "headline": "Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways",
    "summary": "Learn about the promising Monopar Therapeutics Inc. MNPR-101 treatment targeting solid tumors and how it aims to reduce investor risk. Click for more on NMPR.",
    "url": "https://finnhub.io/api/news?id=36bc41a3944ccdc35f83be038b4d5b405c1479bc0e3e2f348b2e1b7d3e2e438a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734963820,
      "headline": "Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways",
      "id": 132122209,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166352596/image_2166352596.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Learn about the promising Monopar Therapeutics Inc. MNPR-101 treatment targeting solid tumors and how it aims to reduce investor risk. Click for more on NMPR.",
      "url": "https://finnhub.io/api/news?id=36bc41a3944ccdc35f83be038b4d5b405c1479bc0e3e2f348b2e1b7d3e2e438a"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea",
    "summary": "Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.",
    "url": "https://finnhub.io/api/news?id=036278801b104c3aafb8898cf8f64368d4d345c1c22428a8f765718d50cb8fed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734963736,
      "headline": "FDA approves Lilly’s obesity med Zepbound to treat obstructive sleep apnoea",
      "id": 132127082,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_1900443067-e1734959444770.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s Zepbound has become the first prescription medicine approved to treat adults with moderate to severe obstructive sleep apnoea (OSA) and obesity.",
      "url": "https://finnhub.io/api/news?id=036278801b104c3aafb8898cf8f64368d4d345c1c22428a8f765718d50cb8fed"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Nordstrom To Go Private",
    "summary": "Department store chain Nordstrom (JWN) has accepted a $6.25 billion all-cash buyout offer to end its 53-year run as a publicly traded company.",
    "url": "https://finnhub.io/api/news?id=cda1d07dc4301357ff00adf0d7f794a87074699afbb53803ed3c773f0b75d715",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734963420,
      "headline": "Wall Street Lunch: Nordstrom To Go Private",
      "id": 132122216,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1468727791/image_1468727791.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Department store chain Nordstrom (JWN) has accepted a $6.25 billion all-cash buyout offer to end its 53-year run as a publicly traded company.",
      "url": "https://finnhub.io/api/news?id=cda1d07dc4301357ff00adf0d7f794a87074699afbb53803ed3c773f0b75d715"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=9acafd37a739d626b16cbf8dbac1782e420263468121da9f87231deff41ac75c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734962418,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 132128415,
      "image": "https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=9acafd37a739d626b16cbf8dbac1782e420263468121da9f87231deff41ac75c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
    "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
    "url": "https://finnhub.io/api/news?id=31cd3e22b1483200418a001b32ab70a52840e9a671ba2882befbfdaa994d9946",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734959760,
      "headline": "Lilly's Zepbound Receives FDA Approval for Sleep Apnea",
      "id": 132121202,
      "image": "https://media.zenfs.com/en/zacks.com/00ec4a55c0f0d99f7e816f5da7894e0c",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "FDA approves LLY's obesity drug Zepbound for its second indication, moderate-to-severe obstructive sleep apnea.",
      "url": "https://finnhub.io/api/news?id=31cd3e22b1483200418a001b32ab70a52840e9a671ba2882befbfdaa994d9946"
    }
  },
  {
    "ts": null,
    "headline": "US FDA revokes authorization for four COVID treatments",
    "summary": "-The U.S. Food and Drug Administration said on Monday it had revoked the emergency use authorization for four COVID-19 treatments, including those from Eli Lilly and Regeneron. ...",
    "url": "https://finnhub.io/api/news?id=c88bd09bd2f95f4f8d9748b82f5edee923c5806cfa3c8d19491c7dd1ce59f316",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734957821,
      "headline": "US FDA revokes authorization for four COVID treatments",
      "id": 132121160,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "-The U.S. Food and Drug Administration said on Monday it had revoked the emergency use authorization for four COVID-19 treatments, including those from Eli Lilly and Regeneron. ...",
      "url": "https://finnhub.io/api/news?id=c88bd09bd2f95f4f8d9748b82f5edee923c5806cfa3c8d19491c7dd1ce59f316"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s UK life sciences investment ‘a pivotal moment’, says analyst",
    "summary": "Eli Lilly’s investment is seen as an opportunity to drive economic growth for the UK while improving public health.",
    "url": "https://finnhub.io/api/news?id=8f6b72983552a5e361e1c807f19995b8b535a9fc3bec8450353f4f079ca875f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734957122,
      "headline": "Eli Lilly’s UK life sciences investment ‘a pivotal moment’, says analyst",
      "id": 132117992,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2024/12/shutterstock_2435952471.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly’s investment is seen as an opportunity to drive economic growth for the UK while improving public health.",
      "url": "https://finnhub.io/api/news?id=8f6b72983552a5e361e1c807f19995b8b535a9fc3bec8450353f4f079ca875f9"
    }
  },
  {
    "ts": null,
    "headline": "US FDA revokes authorization for five COVID treatments",
    "summary": "The U.S. Food and Drug Administration said on Monday it had revoked the emergency use authorization for five COVID-19 treatments, including those from Eli Lilly and Regeneron. ...",
    "url": "https://finnhub.io/api/news?id=54d6ebdd31ffa5e8336c97b8e2cb486ac2f95ba203cdbe9aec5d199bdf7d26e6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734956738,
      "headline": "US FDA revokes authorization for five COVID treatments",
      "id": 132120996,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The U.S. Food and Drug Administration said on Monday it had revoked the emergency use authorization for five COVID-19 treatments, including those from Eli Lilly and Regeneron. ...",
      "url": "https://finnhub.io/api/news?id=54d6ebdd31ffa5e8336c97b8e2cb486ac2f95ba203cdbe9aec5d199bdf7d26e6"
    }
  },
  {
    "ts": null,
    "headline": "Hot Obesity Drug Market Will Keep Investors Gripped Next Year",
    "summary": "(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNovo sh",
    "url": "https://finnhub.io/api/news?id=8627274ffe00c98c4f130143de0907fd1d833a955e597066c397b45dfb1c4edc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734956524,
      "headline": "Hot Obesity Drug Market Will Keep Investors Gripped Next Year",
      "id": 132117993,
      "image": "https://media.zenfs.com/en/bloomberg_markets_842/d6d8e08ee049366cd32f1c0ad2b087b7",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Disappointing trial results for Novo Nordisk A/S’s experimental obesity shot capped a volatile year for investors in drug developers vying for a piece of pharma’s hottest market.Most Read from BloombergReviving a Little-Known Modernist Landmark in BuffaloThe Architects Who Built MiamiHo Chi Minh City Opens First Metro Line After Years of DelayNew York’s Congestion Pricing Plan Still Faces Legal HurdlesNew York City’s Historic Preservation Movement Is Having a Midlife CrisisNovo sh",
      "url": "https://finnhub.io/api/news?id=8627274ffe00c98c4f130143de0907fd1d833a955e597066c397b45dfb1c4edc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company - FDA approves Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity",
    "summary": "INDIANAPOLIS - Eli Lilly and Company today announced the U.S. Food and Drug Administration approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe...",
    "url": "https://finnhub.io/api/news?id=e7a98f33320cafdc74af137fa7b8fcb50819ac77a4781e417cb613929cabd7dd",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734953113,
      "headline": "Eli Lilly and Company - FDA approves Zepbound as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity",
      "id": 132120259,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Eli Lilly and Company today announced the U.S. Food and Drug Administration approved Zepbound as the first and only prescription medicine for adults with moderate-to-severe...",
      "url": "https://finnhub.io/api/news?id=e7a98f33320cafdc74af137fa7b8fcb50819ac77a4781e417cb613929cabd7dd"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Honda, Nissan, Qualcomm, Eli Lilly, Tesla, Rumble, and More",
    "summary": "Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s Zepbound for some sleep-apnea patients.",
    "url": "https://finnhub.io/api/news?id=5566e283061d879ebf86a280606232f2005fac2a1c2bc7026529da7db1617269",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734949560,
      "headline": "These Stocks Are Moving the Most Today: Honda, Nissan, Qualcomm, Eli Lilly, Tesla, Rumble, and More",
      "id": 132117342,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Honda and Nissan begin merger talks with a plan for the combination to be completed in 2026, Qualcomm scores a victory in its licensing dispute with Arm Holdings, and the FDA approves Eli Lilly’s Zepbound for some sleep-apnea patients.",
      "url": "https://finnhub.io/api/news?id=5566e283061d879ebf86a280606232f2005fac2a1c2bc7026529da7db1617269"
    }
  },
  {
    "ts": null,
    "headline": "Does This News From the FDA Make Eli Lilly a Buy for 2025?",
    "summary": "Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market.  Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro.  Demand has been so strong, that it earlier surpassed supply and pushed Lilly to increase its manufacturing capacity to keep up.",
    "url": "https://finnhub.io/api/news?id=ed41bbe2467f9c0d8a91d5031117701e52ef5b134fd06f1a3067a1a12cd8610d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734945300,
      "headline": "Does This News From the FDA Make Eli Lilly a Buy for 2025?",
      "id": 132117343,
      "image": "https://g.foolcdn.com/editorial/images/801727/gettyimages-1178121483.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market.  Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro.  Demand has been so strong, that it earlier surpassed supply and pushed Lilly to increase its manufacturing capacity to keep up.",
      "url": "https://finnhub.io/api/news?id=ed41bbe2467f9c0d8a91d5031117701e52ef5b134fd06f1a3067a1a12cd8610d"
    }
  },
  {
    "ts": null,
    "headline": "Most significant clincal trials of 2024",
    "summary": "From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.",
    "url": "https://finnhub.io/api/news?id=603d874a80c5321226f413a1fd3a45790a2dff29c389feb9b5582b259387d3e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734944400,
      "headline": "Most significant clincal trials of 2024",
      "id": 132117136,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2024/12/2024.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "From GLP-1RA and HIV PrEP successes, to flops in DMD and Alzheimer’s, Clinical Trials Arena rounds up the biggest trial read outs of 2024.",
      "url": "https://finnhub.io/api/news?id=603d874a80c5321226f413a1fd3a45790a2dff29c389feb9b5582b259387d3e4"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Growth Opportunities Fund Q3 2024 Commentary",
    "summary": "The Hartford Growth Opportunities Fund (I Share) underperformed the Russell 3000 Growth Index during the quarter, however delivered overall positive returns. Read more here.",
    "url": "https://finnhub.io/api/news?id=54f9d904961b49bbf5bdaf2ca2c5ab979fb0d4fcf62f6e5860e7c3dab31aa30e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734933000,
      "headline": "Hartford Growth Opportunities Fund Q3 2024 Commentary",
      "id": 132117056,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400960132/image_1400960132.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Growth Opportunities Fund (I Share) underperformed the Russell 3000 Growth Index during the quarter, however delivered overall positive returns. Read more here.",
      "url": "https://finnhub.io/api/news?id=54f9d904961b49bbf5bdaf2ca2c5ab979fb0d4fcf62f6e5860e7c3dab31aa30e"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Healthcare Fund Q3 2024 Commentary",
    "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=437ec63326aa68c908ac079db97d70f4234eaaad235650d5fe23a7620a6c7827",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734930900,
      "headline": "Hartford Healthcare Fund Q3 2024 Commentary",
      "id": 132116815,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2154850841/image_2154850841.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=437ec63326aa68c908ac079db97d70f4234eaaad235650d5fe23a7620a6c7827"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: FDA approves apnea treatment",
    "summary": "The FDA approves Zepbound® as the first and only prescription drug for moderate-to-severe obstructive sleep apnea in obese adults.Zepbound can help adults with moderate-to-severe obstructive sleep...",
    "url": "https://finnhub.io/api/news?id=aaed41c553ddaee9c18f016cdd45fe362e2c21ffd937276a7c8ecd07339893f1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734927617,
      "headline": "Eli Lilly: FDA approves apnea treatment",
      "id": 132116522,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "The FDA approves Zepbound® as the first and only prescription drug for moderate-to-severe obstructive sleep apnea in obese adults.Zepbound can help adults with moderate-to-severe obstructive sleep...",
      "url": "https://finnhub.io/api/news?id=aaed41c553ddaee9c18f016cdd45fe362e2c21ffd937276a7c8ecd07339893f1"
    }
  },
  {
    "ts": null,
    "headline": "Tracking Philippe Laffont's Coatue Management Portfolio - Q3 2024 Update",
    "summary": "Coatue Management's 13F portfolio increased from $25.69B to $26.92B. Click here for a detailed analysis.",
    "url": "https://finnhub.io/api/news?id=3a0ce3b009051f6ec77df1457126f3d55d4c025c525ef846af9e14fd619bf3e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734915600,
      "headline": "Tracking Philippe Laffont's Coatue Management Portfolio - Q3 2024 Update",
      "id": 132115539,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/472298390/image_472298390.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Coatue Management's 13F portfolio increased from $25.69B to $26.92B. Click here for a detailed analysis.",
      "url": "https://finnhub.io/api/news?id=3a0ce3b009051f6ec77df1457126f3d55d4c025c525ef846af9e14fd619bf3e3"
    }
  }
]